Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Recurrence × Bevacizumab × Clear all

Phase

Phase 2 21 Phase 1 5 Phase 3 4 Phase NA 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 10 Colonic Neoplasms 4 Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Rectal Neoplasms 2 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Astrocytoma 2 Vipoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Recurrence 1 Progression Free Survival 1 Oropharyngeal Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1 Laryngeal Neoplasms 1 Insulinoma 1 Inflammatory Breast Neoplasms 1 Hypopharyngeal Neoplasms 1 Glucagonoma 1

Interventions

Temozolomide 3 Etoposide 3 pembrolizumab 2 Lomustine 2 Haloperidol 2 Gemcitabine 2 Cyclosporine 2 vocimagene amiretrorepvec 1 trofosfamide 1 ruxolitinib 1 regorafenib 1 peginterferon alfa-2b 1 osimertinib 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 imetelstat 1 glumetinib 1 etoposide phosphate 1 eculizumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 carbon-11 acetate 1 auricularum 1 aldesleukin 1 Thiotepa 1 Sirolimus 1 Rituximab 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡